Posts Tagged ‘Aduhelm’
Health payers–including Medicare and Point32Health–to question Aduhelm pricing and its “reasonable and necessary” use
State’s Second-Largest Health Insurer Slams Biogen For Costly Alzheimer’s Drug (The Boston Globe): The state’s second-biggest health insurer is threatening to limit or not cover Biogen’s new Alzheimer’s drug, accusing the Cambridge biotech of putting “excessive corporate profits” ahead of patients by charging $56,000 a year for the controversial treatment. Michael Sherman, chief medical officer…
Read MoreCan the controversial FDA approval of Aduhelm backfire and delay the discovery of actual Alzheimer’s treatments? (Yes, it can)
The U.S. Food and Drug Administration (FDA) recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community. Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead…
Read MoreUS Senator Joe Manchin calls for a new FDA Commissioner to replace current (acting) one who “has repeatedly ignored public health concerns and shown a dereliction of duty” over opioids and aducanumab
Key Democrat Manchin Bashes FDA Leader on Alzheimer’s Approval (Bloomberg): Senator Joe Manchin, a moderate Democrat considered a crucial vote within the party’s slim Senate majority, said Janet Woodcock, the temporary head of the Food and Drug Administration, should be quickly replaced with a permanent leader. Manchin blasted an FDA decision to approve the controversial…
Read MoreFirst, do no harm? Six reasons to approach anti-amyloid drug Aduhelm cautiously, if at all
6 ways the FDA’s approval of Aduhelm does more harm than good (STAT News): Like many people, I was shocked when the Food and Drug Administration ignored the advice of its neurological drugs advisory panel and broadly approved Biogen’s new drug, Aduhelm, even for populations never included in the clinical trials to assess the drug.
Read MoreGrowing backlash against the FDA approval of unproven Alzheimer’s treatment Aduhelm, by Biogen
ICER Issues Statement on the FDA’s Approval of Aducanumab for Alzheimer’s Disease (Institute for Clinical and Economic Review): The Institute for Clinical and Economic Review (ICER) believes that the FDA, in approving aducanumab (Aduhelm™, Biogen) for the treatment of Alzheimer’s disease, has failed in its responsibility to protect patients and families from unproven treatments with…
Read More